reason report
final england reimburs doublet tripl appear
horizon
bottom line morn vertex announc reach
agreement nh england reimburs within
day patient england wale northern ireland
patient elig orkambi age
symkevi age agreement also expand
access kalydeco patient part uk
mutat previous cover exist
reimburs agreement kalydeco announc
open door addit patient treat
vertex medicin howev agreement also lock
vertex complet review two product
well tripl combin approv
sign vertex oblig bound find
pharmacoeconom assess time process
mean reimburs tripl combin uk
perhap later later previous expect
negoti price disclos expect
part uk pay
vertex medicin materi germani us
price rang ultim also appli tripl
price current gbp list price orkambi
mean uk second-largest market cystic fibrosi cf
medicin abl claim secur lowest develop
world price medicin penetr ramp next
month agreement gener increment revenu
vertex sale orkambi symkevi
england northern ireland wale effect boost compani
ex-u sale compar current run rate current sale
vertex cf medicin uk includ revenu kalydeco
anticip formal reimburs
uk would receiv tripl combin
approv initi reimburs part europ given
materi news expect updat market compani
forecast inform plan revisit model updat
ou forecast account addit uk sale
vertex made signific progress ou reimburs sinc
past week spain australia england sinc
septemb scotland ou countri includ uk
germani eu countri agreement expect
french govern conclud price negoti
compani soon current expect vertex submit ema regulatori
file tripl combin later year like approv
late earli also expect compani reach
pleas refer page import disclosur price chart analyst certif
reimburs agreement major eu countri tripl
rel quickli approv
base latest result total ou sale cf drug
reach growth yoy high growth
primarili driven strong sale germani due launch symkevi
current forecast total ou sale reach
grow slightli reach given
agreement like revenu orkambi symdeko/
symkevi grow faster previous forecast least
next year
geoffrey porg mbb certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori vertex pharmaceut incorpor
leerink place outperform rate februari
creat bluematrix
price target vertex base simpl averag three approach believ reason
basi valu stock today approach simpl price earn multipl higher growth larg cap
biopharmaceut compani price sale multipl mid larg cap high growth biopharmaceut compani
discount cash flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim discount back year
compani cost equiti give valu one year use averag high growth larg cap biotech price-
to-revenu multipl sale appli
revenu estim post-tripl discount back year compani cost equiti give
valu one year lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price target upon complet
analysi quarterli result revisit price target present remain unchang
risk valuat
risk view outlook valuat vertex includ major chang price reimburs
coverag label competit posit kludger iambi compani main product today major
risk disappoint delay failur compani develop regulatori file novel tripl
combin medicin cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cf tr altern approach
treat cf gene therapi final compani histori spend much potenti earn
expens diversifi acquisit could undermin futur expect valu compani cf portfolio
opportun better-than expect perform includ realiz signific revenu compani
current cf dual combin market outsid us well acceler clinic develop tripl
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
